Join us March 10 for the Hepatitis B Foundation Gala <<Click here>>

News Archive

03/23/2022: New Hepatitis D Central Resource Available from Healio

02/22/2022: We Should Be Screening Now for HDV with Emerging Drug Therapies in Phase 3

02/17/2022: Four Questions with Professor Maria Buti: Understanding Hepatitis D

02/11/2022: New Hepatitis Delta Podcast Episode: Viral Hepatitis: On the Road to Elimination

02/04/2022: Patient Perspective: Living with HBV and HDV Coinfection in Pandemic Times

01/20/2022: Hepatitis D Changing Context Global Prevalence

01/04/2022: New Slideset Updated on Don't Delay with Delta: Best Practices and Calls to Action in HDV

12/21/2021: Bulevirtide Improves Quality of Life in Chronic HDV

12/21/2021: Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection

12/20/2021: Medical Minutes Podcasts on HDV Epidemiology and Universal Screening

12/18/2021: Large Proportion of Undiagnosed Anti-HDV Positive Individuals Due to Lack of Testing

12/16/2021: UN Adopts Resolution on Rare Diseases

12/13/2021: Bulevirtide Shows Real-World Efficacy Versus HDV

12/03/2021: Should We Screen All Patients with Hepatitis B for Hepatitis Delta?

12/01/2021: Hepatitis Delta Presentations from the 2021 AASLD Liver Meeting Now Available

12/01/2021: Ethnic Variations in Clinical Presentation and Treatment Eligibility for HDV Infection at a US Referral Center

11/19/2021: Gilead Files BLA for Bulevirtide to Treat Chronic HDV Infection

11/12/2021: Prevalence and Characteristics of Hepatitis Delta in the United States: An Analysis of All-Payer Claims Databases

09/29/2021: The Kinesin KIF4 Mediates HBV/HDV Entry Through Regulation of Surface NTCP Localization and Can Be Targeted by RXR Agonists in vitro

08/24/2021: The Highly Complementary Model of Hepatitis D and Hepatitis B, Described by Scientists, Can Broadly Cover the HDV Replication Cycle

07/28/2021: Hepatitis D: Neglected Disease in the Race to Eliminate Viral Hepatitis by 2030

07/27/2021: Risk of Hepatocellular Carcinoma in Hepatitis B & D Virus Co-Infected Patients: A Systematic Review and Meta-Analysis of Longitudinal Studies

07/12/2021: Significant Disruptions in the International Incidence of Hepatitis Delta Virus

06/25/2021: Gilead Preps Filing for Hepatitis D Therapy Hepcludex in US

06/24/2021: Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks

04/01/2021: Hepatitis Delta Infection Among Persons with HIV in Europe

11/30/20: New Insights into Hepatitis D Virus Persistence: The Role of Interferon Response and Implications for Upcoming Novel Therapies

11/17/20: Eiger Announces Positive Peginterferon Lambda-Lonafarnib Combination End-of-Study Results from Phase 2 LIFT HDV Study at the Liver Meeting Digital Experience 2020

11/16/20: Eiger Announces Case Studies Demonstrating Regression of Liver Fibrosis Following 48 Weeks of Therapy with Peginterferon Lambda in Patients with Chronic HDV Infection at the Liver Meeting Digital Experience 2020

10/7/20: Risk Factors for Delta Hepatitis in a North American Cohort: Who Should Be Screened? 

9/17/20: Hepcludex Launched in Germany, France, and Austria

8/31/20: End of Treatment Results Presented for Lambda-Interferon + Lonafarnib Combination Phase 2 LIFT Study at International Liver Congress, 2020

8/5/20: Hepcludex Approved by European Commission

6/2/20: MYR Pharmaceuticals Receives Positive Opinion from EMA for Hepcludex for the Treatment of Chronic Hepatitis Delta

2/18/20: New Insights into Hepatitis B and Hepatitis Delta Virus Entry

2/1/20: The Effect of Twelve Weeks of Treatment with Ezetimibe on HDV RNA Level in Patients with Chronic Hepatitis D

1/2/20: Hepatitis Delta Has Higher Health Care Cost Burden Than Hepatitis B

12/26/19: REP2139 Demonstrates Functional Cure in Both HBV, HDV 

11/12/19: Eiger Announces Phase 2 LIFT Study Results During AASLD 2019

11/1/19: MYR Pharmaceuticals to Present on Myrcludex B During AASLD 2019

11/1/19: FDA Guidance to Help with Hepatitis Delta Drug Development

8/20/19: Pegylated Interferon Lambda Receives FDA Breakthrough Therapy Designation

7/29/19: Russia Plans Production of Myrcludex B

4/13/19: MYR Announces Phase 2 Myrcludex B Trial Data at The International Liver Congress 2019

4/11/19: Eiger Announces Phase 2 LIMT Hepatitis Delta Study Progress at The International Liver Congress 2019

3/5/19: MYR Pharma Announces Grant of Promising Innovative Medicine (PIM) Designation by British MHRA for Myrcludex B

12/18/18: Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib

12/17/18: Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib

9/28/18: Global Hepatitis Delta Rates Highest Among HBV Coinfected with Risky Behaviors

6/4/18: Digestive Disease Week: Hepatitis Delta: The 'Forgotten Virus' is Still Here

10/23/18: MYR Pharma Announces FDA Breakthrough Therapy Designation for Myrcludex B

9/5/17:  Pegylated Interferon Lambda Receives FDA Orphan Drug Designation

7/27/17: Pegylated Interferon Lambda Receives FDA Fast Track Designation 

5/25/17: MYR Pharma Announces Myrcludex B PRIME Designation by the EMA

12/23/14: EB Pharma Announces License Agreement for Tipifarnib from Janssen Pharmaceutica for Development in Hepatitis Delta 

12/22/14: Lonafarnib Recieves Orphan Drug Designation by FDA and EMA